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Introduction: Sentinel node mapping with radioactive technetium
in non-small cell lung cancer has been shown to be feasible in
several single institution reports. The Cancer and Leukemia Group
B designed a phase II trial to test a standardized method of this
technique in a multi-institutional setting. If validated, the technique
could provide a more accurate and sensitive way to identify lymph
node metastases.
Methods: Patients with clinical stage I non-small cell lung cancer
amenable to resection were candidates for this trial. Intraoperatively,
tumors were injected with technetium sulfur colloid (0.25 mCi). The
tumor and lymph nodes were measured in vivo with a hand held
Geiger counter and resection of the tumor and nodes was carried out.
Sentinel nodes, all other nodes and the tumor were analyzed with
standard histologic assessment. Negative sentinel nodes were also
evaluated with immunohistochemistry.
Results: In this phase II trial, 8 surgeons participated (1–13 patients
enrolled per surgeon), and 46 patients (out of a planned 150) were
enrolled. Of these, 43 patients had cancer and an attempted complete
resection, and 39 patients underwent sentinel node mapping. One or
more sentinel nodes were identified in 24 of the 39 patients (61.5%).
The sentinel node(s) were found to be accurate (no other nodes were
positive for cancer if the sentinel node was negative) in 20/24
patients (83.3%). In the overall group the sentinel node mapping
procedure was found to be accurate in 20/39 patients (51.2%).
Conclusions: Intraoperative sentinel node mapping in lung cancer
with radioisotope yielded lower accrual and worse accuracy than
expected. The multi-institutional attempt at validating this technique
was unsuccessful.
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In the United States, lung cancer remains the number onesource of cancer-related mortality in both men and women.
Over 160,000 deaths will be attributed to lung cancer in
2008.1 Complete surgical resection for localized disease is the
most viable option for sustained remission or cure. Nonethe-
less the 5 year survival after complete resection of stage I
tumors is only 60 to 70%. The patients who relapse after
complete resection of stage I (lymph node negative) tumors
by definition had occult disease at the time of their initial
surgery.
Sentinel node mapping techniques have been applied to
the resection and treatment of nearly all solid tumors with
varying success and acceptance. The technique employs a
lymphatic tracer (most commonly radioisotope or blue dye).
The tracer is injected into the tumor and followed by visual-
ization or gamma counter measurements of individual lymph
nodes to determine the first site of efferent lymphatic drain-
age from a tumor. This sentinel node (SN) station should be
the first site of lymphatic involvement if metastases have
occurred.
SN assessment has become standard of care in breast
cancer and melanoma surgery. The greatest utility of the
technique in these cancers is the avoidance of nontherapeutic
axillary or groin lymph node dissections and their incumbent
morbidities. In lung cancer surgery, the adoption of SN
identification has been slow in part because the morbidity of
mediastinal lymph node dissection is not as significant as in
breast and melanoma surgery. An equally important potential
utility of SN mapping is the ability to direct pathologic
examination and more sensitive techniques to detect occult
micrometastatic disease.
The technique of radioactive tracer injection at the time
of thoracotomy or thoracoscopy (video-assisted thoraco-
scopic surgery), in vivo and ex vivo mapping methods as
described by Liptay2 was employed in this phase II trial to
investigate the feasibility of sentinel lymph node mapping in
a multi-institutional protocol sponsored by the Cancer and
Leukemia Group B.
In previous studies of the intraoperative technetium
injection technique, several unsuccessful SN mapping efforts
were originally attributed to clinically positive lobar or hilar
nodes that resulted in lymphatic obstruction and tracer mi-
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gration elsewhere. By using only clinically stage I patients,
we had hoped to improve upon the results of single institution
studies.
METHODS
Eligibility
Patients over 18 years of age with good performance
status (Eastern Cooperative Oncology Group 0–2) with clin-
ically diagnosed stage I lung cancers were considered for
enrollment in this phase II feasibility trial. Patients with prior
treatment for their lung cancers or thoracic radiation were
excluded from enrollment. The trial opened in September
2004 with an accrual goal of 150 patients. It was closed
before full accrual in November 2006.
Histologic confirmation of cancer was not required
before enrollment. Mediastinoscopy was allowed but not
required and when done was encouraged to be at a separate
setting from the SN and resection procedure. All patients
were provided with informed consent that complied with the
National Cancer Institute guidelines, the Cancer and Leuke-
mia Group B (CALGB) and local Institutional Review
Boards.
Study Objectives
The primary objective of this study was to assess the
feasibility and accuracy of intraoperative sentinel lymph node
mapping in patients with resectable clinical stage I lung
cancer in a multicenter setting by (1) SN identification rate
(percentage of patients with lung cancer in whom at least
1 SN is identified) and (2) the accuracy rate, which reflects
those patients with identified SNs positive for metastatic
disease, and those with SNs negative for metastatic disease
who do not have metastases in any other intrathoracic
lymph nodes.
Secondary objectives were to evaluate the percentage
of patients upstaged by the detection of micrometastases in
SNs, the relationship between micrometastases and survival
and the percentage of patients with skip metastases pattern
(N2) SNs.
Intraoperative Technique
The intraoperative mapping technique was identical to
that described by Liptay2. Briefly, it involved direct injection
of the lung tumor with 0.25 mCi of Technetium Sulfur
Colloid filtered once through a sterile 200 nanometer filter.
After initial thoracotomy or thoracoscopic exploration, the
tumor was injected with technetium-99m sulfur colloid (0.25
mCi) divided into 4 equal doses. Nuclear medicine personnel
were present to assist in preparation of the radioisotope drawn
into 4 tuberculin syringes (1 ml). The isotope was injected
directly into the tumor using 27 gauge needles. During the
time allowed for migration of the radioactivity through the
lymphatics, care was taken to avoid disrupting the peribron-
chial tissues where the majority of lymphatic channels reside.
The migration of the radioisotope was tracked through
the lymphatics by a hand held gamma probe (Navigator, Tyco
Corporation). The tumor and nodal stations were initially
surveyed in the thorax and background levels recorded within
the mediastinum, distant from the primary tumor. Because the
initial in vivo readings may often be confounded by shine-
through effect of radioactivity of the tumor, final confirma-
tory readings were taken ex vivo. Visible mediastinal, hilar,
and peribronchial lymph nodes were dissected and measured
separately from the tumor specimen after removal from the
chest (ex vivo).
Migration of the technetium sulfur colloid solution was
considered successful if a specific nodal station registered
counts per second (cps) greater than three times background
values. All lymph nodes with ex vivo cps greater than this
level were classified as SNs.
After the initial scintographic readings and standard
anatomic resection with ipsilateral mediastinal node dissec-
tion was completed, repeat gamma probe examination was
performed to assess for residual radioactivity and potentially
overlooked lymph nodes. Reresection of nodal stations was
performed based on the handheld gamma counter readings
and visual inspection.
Lymphadenectomy and Pathologic Evaluation
A full hilar and mediastinal node dissection was re-
quired. A minimum of 5 lymph node stations were required
based on the tumor location. Every effort was made to
remove nodes in their entirety.
After SN identification, SNs were examined first with
standard histology with hematoxylin and eosin (H&E) using
conventional bi-valving techniques. If initial histologic ex-
amination was negative for metastases, at least 3 serial (step)
sections at 30 to 40 m intervals were evaluated. In addition,
initially negative SNs were examined with immunohisto-
chemistry using the AE1/AE3/PCK26 cytokeratin antibody
(Ventana Medical Systems Inc, Tucson, AZ) according to
standard protocol. Immunohistochemistry was considered
positive if it demonstrated positive cell clusters or individual
cells with the appropriate tumor cell morphology.
RESULTS
The planned accrual target for this study was 150
patients. The trial was terminated early based on disappoint-
ing accuracy, slower than expected accrual and reduced
National Cancer Institute funding. Difficulties with radiation
safety requirements and challenges to collaboration between
specialties (surgery, nuclear medicine, and pathology) im-
paired accrual at some institutions.
Forty-six patients with suspected localized lung cancer
were initially registered to participate. Of these, 44 patients
were diagnosed with potentially resectable non-small cell
lung cancer. Five patients did not undergo the SN procedure
(Radio-isotope not available, [1] patient withdrew consent,
[2] Metastatic disease found [1] and unknown reasons [1]).
The remaining 39 patients with clinical stage I tumors
underwent an attempted intraoperative SN mapping proce-
dure with the injection of technetium sulfur colloid. The
demographic information on the participating patients is sum-
marized in Table 1. There were 22 men and 17 women with
a mean age of 68 (range, 46–85). Adenocarcinoma was the
most commonly encountered cell type and the upper lobes
were the most frequently involved lobes. All patients had
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clinical stage I tumors. Thirty of the 39 patients had node
negative stage I tumors (Table 1).
Eight surgeons participated in this national trial spon-
sored by the Cancer and Leukemia Group B. Surgeons
enrolled between 1 and 13 patients. Before participating,
surgeons were required to view an instructional video and
complete and pass a quiz on the technical aspects of the
intraoperative SN mapping procedure (Table 2).
Of the 39 patients injected with the radioactive tracer,
at least one specific SN was identified in 24 (61.5%) (Table
2). The SNs was accurately classified in 20 of those 24
patients (83.3%). This accuracy was defined by either a
positive SN, or no other positive lymph nodes found when the
SN was negative for metastatic involvement. This was an
overall accuracy rate of 51.2% (20 of 39 patients) (Table 3).
No specific pattern of failure to identify SNs or detect
migration of the radioisotope through the lymphatics was
noted in relation to specific lobar involvement or ultimate
pathologic stage.
Of the 39 patients, 9 had pathologically identified
positive lymph nodes. A SN was identified in six of these
nine patients but was accurate (i.e.,: pathologically involved
as well as the other involved nodes) in only two out of the six
patients. In these two cases the SN was negative on standard
H&E staining but cancer cells were identified on immuno-
histochemistry for epithelial markers in the nodal tissue. An
overall accuracy rate was 51.2% (20 of 39).3
DISCUSSION
Sentinel node identification has become standard of
care in melanoma and breast cancer surgical care. The idea of
a first nodal station draining a tumor theoretically would
allow the assessment of that node(s) to represent the state of
the remaining regional nodes. The SN is used to limit poten-
tially morbid lymph node dissections. Another benefit of the
technique is directing applications of more focused patho-
logic or molecular staging techniques (Serial sections, Immu-
nohistochemistry, reverse transcription-polymerase chain re-
action etc.). This ability to direct a more focused search for
metastatic disease in the SN rather than all of the nodes
removed is a primary benefit of the technique in lung cancer.
With current indications for adjuvant chemotherapy in
resected lung cancer largely based on the status of the
TABLE 1. Demographics/Tumor Stage
Patients M/F 22/17
Age–mean (range) 68 (46–85)
Race–White/Black 37/2
ECOG PS 0/1 35/4
Tumor cell type N
Adenocarcinoma 22
Squamous cell 11
Large cell 3
Bronchioalveolar cell 3
Pathologic stage
IA T1N0 16
IB T2N0 14
IIA T1N1 2
IIB T2N1 4
IIIA T1N2 2
IIIA T2N2 1
Lobe involved
Left upper 11
Right upper 10
Right lower 10
Left lower 5
Right middle 3
M, male; F, female; ECOG, Eastern Cooperative Oncology Group; PS, performance
status.
TABLE 2. Sentinel Node Accuracy by Surgeon/Location/
Stage
Surgeon N SN ID Accuracy
A.
A 13 9/13 7/9
B 6 5/6 5/5
C 7 4/7 4/4
D 5 2/5 2/2
E 3 1/3 1/1
F 2 2/2 1/2
G 2 0/2 —
H 1 1/1 0/1
Totals 39 24/39 20/24
B.
Lobe
LUL 11 5/10 4/5
RUL 10 7/9 5/7
RLL 10 4/9 4/4
LLL 5 4/6 3/4
RML 3 2/3 2/2
C.
Pathologic stage
IA T1N0 16 9/16 9/9
IB T2N0 14 9/14 9/9
IIA T1N1 2 0/2 —
IIB T2N1 4 4/5 2/4
IIIA T1N2 2 1/2 0/1
IIIA T2N2 1 1/1 0/1
SN, sentinel node; LUL, left upper lobe; RUL, right upper lobe; RLL, right lower
lobe; LLL, left lower lobe; RML, right middle lobe.
TABLE 3. Pathologic Nodal Status
Number
Sentinel negative, other node(s) negative 18
Sentinel negative, other node(s) positive 4
Sentinel node positive, other node(s) negativea 2a
Sentinel node positive, other node(s) positive 0
No sentinel node identified, all nodes negative 12
No sentinel node identified, one or more nodes positive 3
Total patients 39
a Only positive with serial sections (1) and immunohistochemistry (1).
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locoregional lymph nodes, the accurate identification of pos-
itive nodes has gained therapeutic importance.
Intraoperative Tracer Injection
Sentinel node mapping in lung cancer was first reported
by Little et al.4 in 1999. They used blue dye and found a less
than 50% success rate with the main impediment being
difficulty distinguishing blue dyed nodes from black anthra-
cotic nodes. Intraoperative radionuclide mapping techniques
reported improved results of SN identification,5–7 but issues
of shine through effect from the tumor and background
aerosolization of radioactivity made in vivo readings often
unreliable.
The first reported use of intraoperative radioactive
tracer was in 2000.6 The technique used Technitium-99 sulfur
colloid filtered through a 20 m filter. This initial single
institution series demonstrated promise with consistently
short migration times for the radioisotope and reasonably
accurate SN identifications.5,6 Ninety-one patients with oper-
able lung cancer underwent the intraoperative SN technique.
Mean time from injection of the radionuclide to identification
of SN was 63 minutes (range, 23–170). Seventy-eight of the
91 (86%) had a SN identified and 69 of 78 SNs were
classified as true-positives, with no metastases found in other
intrathoracic lymph nodes without concurrent SN involve-
ment. Thus, an accurate SN was identified in 69 of 91 (76%)
patients with lung cancer mapped with intraoperative techne-
tium radionuclide. Metastatic disease was found in 21 (27%)
of the 78 identified SNs. In 9 of these 21 patients, the SN was
the only positive node. In 7 (77%) of these 9 patients, the SN
was negative by conventional histology and only harbored
micrometastatic disease detected by either serial sectioning or
immunohistochemistry.5
Since these initial reports, other single institutional
groups have reported SN identification rates of 74% with
Technitium alone7 and 81% using a combination of techne-
tium and blue dye.8 In contrast, the accepted accuracy rate of
SN identification in breast cancer is over 95%. While the use
of radionuclide in lung cancer mapping techniques reported
improved results of SN identification, issues of shine through
effect from the tumor and background aerosolization of
radioactivity made in vivo readings often unreliable and ex
vivo readings were required for accurate SN identification.
CALGB 140203 opened for accrual in September 2004.
After 2 years, 46 of the planned 150 patients were accrued.
Factors affecting accrual and accuracy rates included barriers
to cooperation between nuclear medicine, surgery and pathol-
ogy for intraoperative use of radioactivity and intensified
pathologic evaluation along with various state regulations for
radioactivity handling complicating the protocol.
The disappointing 51.2% SN identification rate in our
series might have been due in part to a learning curve
potentially not overcome by the time of the study’s termina-
tion. Eight surgeons participated in the study for an average
of 5 cases and range between 1 and 13.
Preoperative Tracer Injection
Transportation and handling of the radioisotope in the
operating room adds a layer of complexity to the intraoper-
ative SN procedure in lung cancer. Preoperative transthoracic
injection, usually under CT guidance, has some logistical
benefits. It allows the injection to be done in radiology or
nuclear medicine and avoids the intraoperative handling of
radioisotope. However, the risks of pneumothorax, bleeding
and seeding of tumor along needle tracts are all at least
theoretical concerns.
Because of restrictions in the use and handling of
radioactive substances in Japan, Japanese surgeons have been
pioneers in the preoperative injection of radioactive tracer for
SN mapping in lung cancer. Technetium Tin Colloid has been
the most reported. With its higher mass, the migration time is
prolonged enough to have the CT guided injection the day
before surgery.
Nomori et al.9 have reported the largest experience.
Most recently, they report an 83% SN identification rate in 53
patients with small clinical T1N0 tumors considered for
segmentectomy. Their SN guided segmentectomy resulted in
positive SNs on frozen section leading to completion lobec-
tomies in three patients.
Nonradioactive Tracers
Several groups have moved on to study new techniques
to nodal mapping which do not rely on radioactive materials
and have had promising results. Soltecz et al.10 reported on
the use of quantum dots that fluoresce in the near infrared
spectrum. They used a camera system that simultaneously
acquires color video, the near-infrared fluorescence and a
merged picture to guide dissection. In pigs this technique was
able to reliably identify nodal drainage and SNs. Lymphatics
and nodes were able to be seen through 1 cm of solid tissue
and 5 cm of lung parenchyma. A clinical trial using this
technology in humans with lung cancer is nearing accrual.
Adusumilli et al.11 have recently reported success with
herpes simplex virus containing a green fluorescent protein
transgene. This oncolytic herpes strain was shown to easily
infect cancer cells and track lymphatic metastases within 2 to
4 hours of injection in a murine model. Fluorescent thoracos-
copy could detect these nodal metastases aiding in resection
and due to the oncolytic effect of the virus, a therapeutic
potential was also cited.
Intraoperative FDG-PET
In a pilot study, Nwogu et al.12 injected 10 patients with
10 mCi of F18-fluorodeoxyglucose (FDG) on the day of
surgery. Using a handheld device in surgery they discovered
3 (30%) patients who had FDG positive nodes with micro-
metastases present. This technique differs from a standard SN
mapping as the FDG is selectively taken up by tumor cells
rather than tracking the lymphatic drainage. Further study on
this form of ultra-staging is needed. This is the first study
examining a technique to actually identify metastases and not
the SN that may harbor disease.
The suboptimal results of this phase II trial demonstrate
the limitations of the intraoperative radiotracer technique
requiring collaboration between nuclear medicine, surgery
and pathology disciplines as well as a learning curve that may
not have been completed before its termination.
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Accurate assessment of lymph node status in operable
lung cancer remains critical. This multi-institutional study
sponsored by the CALGB failed to demonstrate the feasibility
of an intraoperative SN mapping technique with a radioactive
technetium-99 tracer. New techniques for both diagnostic SN
mapping potentially coupled with the delivery of therapeutic
agents are under investigation. With the aid of new technol-
ogies and innovation, the surgeon will continue to lead the
diagnosis and treatment of early stage lung cancer.
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